It finally happened. About 10 years after being created, gene-editing specialist CRISPR Therapeutics (NASDAQ: CRSP) earned approval for its first therapy late last year. The treatment in question is called Casgevy and targets sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), two blood-related diseases. This regulatory development was a significant milestone for CRISPR, but the biotech will need more clinical and regulatory success in the years ahead to keep investors happy.

Can CRISPR Therapeutics pull that off? Let's find out how things might evolve for the biotech over the next five years.

CRISPR Therapeutics developed Casgevy with Vertex Pharmaceuticals. So far, the therapy has earned approval in the U.K., the U.S., and Bahrain. More regulatory nods should be coming pretty soon, including in the European Union, Saudi Arabia, and Canada. Of note, Casgevy is the first gene-editing treatment on the market that uses the Nobel prize-winning CRISPR/Cas9 technique.

Continue reading

Source Fool.com